Article Details

Earnings call: Vir Biotechnology reports progress in T-cell engager therapy - Investing.com

Retrieved on: 2024-08-02 21:05:50

Tags for this article:

Click the tags to see associated articles and topics

Earnings call: Vir Biotechnology reports progress in T-cell engager therapy - Investing.com. View article details on hiswai:

Excerpt

T-cell engagers are, in essence, engineered by specific monoclonal antibodies. And given our deep antibody protein engineering and T-cell biology ...

Article found on: www.investing.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo